AR046642A1 - Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil - Google Patents

Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil

Info

Publication number
AR046642A1
AR046642A1 ARP040104271A ARP040104271A AR046642A1 AR 046642 A1 AR046642 A1 AR 046642A1 AR P040104271 A ARP040104271 A AR P040104271A AR P040104271 A ARP040104271 A AR P040104271A AR 046642 A1 AR046642 A1 AR 046642A1
Authority
AR
Argentina
Prior art keywords
spray
composition
volatile
oil phase
pharmaceutical
Prior art date
Application number
ARP040104271A
Other languages
English (en)
Inventor
Franck Pitre
Laurent Fredon
Claire Mallard
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of AR046642A1 publication Critical patent/AR046642A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición en forma de spray que comprende un activo farmacéutico como por ejemplo, un derivado de la Vitamina D, entre otros, al menos una silicona volátil, y una fase aceitosa, no volátil en un medio fisiológicamente aceptable, a su procedimiento de preparación, a su utilización en cosmética y en dermatología. Procedimiento para mejorar la penetración de un activo farmacéutico derivado de la Vitamina D.
ARP040104271A 2003-11-21 2004-11-19 Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil AR046642A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313660A FR2862540B1 (fr) 2003-11-21 2003-11-21 Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile

Publications (1)

Publication Number Publication Date
AR046642A1 true AR046642A1 (es) 2005-12-14

Family

ID=34531173

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104271A AR046642A1 (es) 2003-11-21 2004-11-19 Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil

Country Status (6)

Country Link
US (1) US20070041910A1 (es)
KR (1) KR20060105001A (es)
CN (1) CN1960718A (es)
AR (1) AR046642A1 (es)
FR (1) FR2862540B1 (es)
ZA (1) ZA200605050B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
US8211449B2 (en) * 2004-06-24 2012-07-03 Dpt Laboratories, Ltd. Pharmaceutically elegant, topical anhydrous aerosol foam
ES2407407T3 (es) 2005-06-01 2013-06-12 Glaxosmithkline Intellectual Property Development Limited Formulación de vitamina
FR2893847B1 (fr) * 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un derive de vitamine d et une phase huileuse
EP1970048A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP5978130B2 (ja) 2009-08-14 2016-08-24 バーグ エルエルシー 脱毛症を治療するためのビタミンｄ３およびその類似体
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
RU2639472C2 (ru) 2011-03-14 2017-12-21 Драг Деливери Солюшнз Лимитед Офтальмическая композиция
CA2834301A1 (en) * 2011-05-02 2012-11-08 Lipidor Ab Treatment of psoriasis
WO2014194133A1 (en) * 2013-05-29 2014-12-04 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
SG11201602596UA (en) 2013-10-03 2016-04-28 Dow Pharmaceutical Sciences Stabilized efinaconazole compositions
EP3610891A1 (en) * 2013-11-14 2020-02-19 Lipidor AB Sprayable topical carrier and composition
EP3071295A4 (en) 2013-11-22 2017-05-31 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
CA2998483C (en) 2015-09-16 2022-09-06 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
CN105193723A (zh) * 2015-10-23 2015-12-30 郑州泰丰制药有限公司 度骨化醇喷雾制剂及其制备方法
CN108430439B (zh) 2015-12-18 2021-03-02 帝斯曼知识产权资产管理有限公司 联芳香族维生素d类似物
EP3389606B1 (en) 2015-12-18 2020-07-15 DSM IP Assets B.V. Biaromatic vitamin d analogs
CN108366941B (zh) * 2015-12-18 2021-06-18 帝斯曼知识产权资产管理有限公司 新颖的化合物
EP3389607B1 (en) * 2015-12-18 2020-07-15 DSM IP Assets B.V. Biaromatic vitamin d analogs
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
CN112165949A (zh) 2018-03-16 2021-01-01 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗宫颈上皮内瘤变(cin)和宫颈癌的局部疗法
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
US4889845A (en) * 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
FI872553A (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Medium foer laekemedel foer lokalt bruk.
JPH02145512A (ja) * 1988-11-26 1990-06-05 Shin Etsu Chem Co Ltd 被膜形成型外用剤
GB9109733D0 (en) * 1991-05-07 1991-06-26 Unilever Plc Cosmetic composition
JPH07118596A (ja) * 1993-10-25 1995-05-09 Daikin Ind Ltd 撥水撥油剤組成物およびその製法
US6538039B2 (en) * 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
US6231844B1 (en) * 1995-04-13 2001-05-15 The Procter & Gamble Company Nonionic surfactant foaming agents for foaming cosmetic compositions
FR2740038B1 (fr) * 1995-10-20 1998-01-02 Lafon Labor Composition pour l'administration transdermique
EP0966972B1 (en) * 1998-06-18 2003-09-24 Dow Corning France S.A. Topical composition containing silicon gum
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
FR2785284B1 (fr) * 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6410038B1 (en) * 2000-06-14 2002-06-25 Dow Corning Corporation Water-in-oil-in-polar solvent emulsions
US7655717B2 (en) * 2002-07-17 2010-02-02 Mary J. Goulbourne Ointment composition for treating decubitus ulcers and methods for its making and its use

Also Published As

Publication number Publication date
US20070041910A1 (en) 2007-02-22
FR2862540A1 (fr) 2005-05-27
ZA200605050B (en) 2007-11-28
FR2862540B1 (fr) 2007-03-30
KR20060105001A (ko) 2006-10-09
CN1960718A (zh) 2007-05-09

Similar Documents

Publication Publication Date Title
AR046642A1 (es) Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil
AR044872A1 (es) Composicion pulverizable que comprende un activo farmaceutico al menos una silicona volatil y una fase aceitosa no volatil
CY1107942T1 (el) Ψεκασιμη συνθεση για τη χορηγηση παραγωγων της βιταμινης d
CY1107033T1 (el) Συνθεση στη μορφη σπρεϊ η οποια περιλαμβανει ενα συνδυασμο προπιονικης κλομπεταζολης και καλσιτριολης, μια αλκοολικη φαση και μια ελαιωδη φαση
SV2004001691A (es) Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen compuestos y sus usos
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
AR049307A1 (es) Composicion en forma de spray que comprende un corticoide y un derivado de vitamina d, y una fase aceitosa
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
EP2144590A4 (en) TREATMENT COMPOSITIONS FOR THE SKIN AND METHODS
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
CY1109507T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ελαστομερες οργανοπολυσιλοξανιο και μια διαλυτοποιημενη δραστικη ουσια
DE602005003138D1 (de) Zusammensetzung in sprayform mit einer kombination aus clobetasolpropionat und calcitriol, einer alkoholphase und ölphase
NO20091517L (no) Emulsjon
BRPI0518554A2 (pt) uso de um inibidor de pde3
WO2008125771A3 (fr) Utilisation cosmetique d'un extrait de debaryomyces hansenii
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
GB0327390D0 (en) Pharmaceutical formulations
RU2006129597A (ru) Применение ксенона для предотвращения процессов перекисного окисления липидов в пищевых и косметических продуктах, в том числе обогащенных биологически активными веществами
UA94033C2 (en) Use of pde3 inhibitor
AR061769A1 (es) Composicion para el tratamiento de la piel

Legal Events

Date Code Title Description
FB Suspension of granting procedure